- Home
- Products
Tukysa (Tucatinib)
Tukysa (Tucatinib)
- Medicine Name: Tukysa
- Generic Name: Tucatinib
- Dosage Form & Strength: Tablets – 50 mg and 150 mg
- Manufactured By: Seattle Genetics, Inc.
Tukysa is a HER2-targeted kinase inhibitor used in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens.
Recommended Dosage:
- Tucatinib: 300 mg orally twice daily (two 150 mg tablets), approximately 12 hours apart, with or without food
- Capecitabine: 1000 mg/m² orally twice daily, within 30 minutes after meals
- Trastuzumab is administered as per standard protocol
- Tablets must be swallowed whole (not chewed, crushed, or split)
Diarrhea & Dehydration: Can lead to hypotension, acute kidney injury, or death. Initiate antidiarrheal treatment if needed and adjust dose accordingly
Hepatotoxicity: Monitor liver function tests (ALT, AST, bilirubin) before and during treatment. Adjust or discontinue based on severity
Fetal Risk: May cause fetal harm. Use effective contraception:
Females: During treatment and for 7 days after last dose
Males (with partners of reproductive potential): During treatment and for 7 days after last dose
Breastfeeding: Avoid during and for 7 days after final dose
Documents Required to Import Tukysa to India:
- Valid prescription from a licensed oncologist
- Diagnostic reports supporting HER2-positive status
- Government-issued photo ID of the patient
Order Confirmation:
Confirmed only after receipt of documents and import permit (if applicable)
Availability:
Tukysa is available via Global Rare Meds in all major cities including Mumbai, Delhi, Bangalore, Hyderabad, Chennai, Pune, Kolkata, Ahmedabad, Noida, Gurgaon, Lucknow and internationally across South Asia (Afghanistan, Bangladesh, Bhutan, Nepal, Maldives, Sri Lanka, Pakistan).
📞 To Order / Enquire Price:
- Call/WhatsApp: +91-99675 15602
- Email: info@globalraremeds.com
Global Rare Meds sources Tukysa from certified suppliers in the USA, Canada, Europe, and Australia. We ensure:
- Full legal compliance under the Named Patient Import Program
- Prescription validation by licensed pharmacists
- Dispatch from our Fulfillment Center in Ambernath, Thane District
- Secure & timely international or domestic delivery
What is the generic name of Tukysa®?
Tucatinib
Who manufactures Tukysa®?
Seattle Genetics, Inc.
Is Tukysa® FDA approved?
Yes, approved on April 17, 2020
What does Tukysa® treat?
HER2-positive metastatic breast cancer (including brain metastases), in combination with trastuzumab and capecitabine
What dosage forms are available?
Tablets: 50 mg and 150 mg
What are the most common side effects?
Rash, diarrhea, hepatotoxicity, palmar-plantar syndrome, nausea, vomiting, stomatitis, decreased appetite, fatigue, and headache
How should Tukysa be stored?
Store at 20°C to 25°C (68°F to 77°F)
Protect from moisture; retain desiccant in original container
Can pregnant or breastfeeding women take Tukysa?
No. Avoid during pregnancy and for 7 days after last dose. Do not breastfeed during and for 7 days after final dose
Where is Tukysa available in India?
Available in Delhi, Mumbai, Pune, Bangalore, Hyderabad, Chennai, Ahmedabad, Kolkata, Noida, Lucknow, and more
What makes Tukysa unique?
Tukysa targets HER2-positive tumors, including CNS metastases, and is backed by the HER2CLIMB trial showing significant survival benefit
Can I buy Tukysa online from India?
Yes, Global Rare Meds enables legal access to Tukysa under the Named Patient Supply (NPS) with 100% regulatory compliance
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
